Alternativas de Futuro en Cáncer Renal Enrique Grande
|
|
- Gwendolyn Johnson
- 5 years ago
- Views:
Transcription
1 Alternativas de Futuro en Cáncer Renal Enrique Grande Hospital Ramón y Cajal de Madrid
2 The ncreasingly Challenging Field of mrcc Sorafenib (US 2005, EU 2006) 3,4 Sunitinib (US & EU 2006) 3,4 Early 1940s: experiments with cytotoxic chemotherapy 1 High-dose L-2 approved in the US (1995). High treatment-related toxicity; small number of durable responses 2 Temsirolimus and Bevacizumab plus F (US & EU 2007) 3,4 Everolimus (US & EU 2009) 3,4 Axitinib (US & EU 2012) Early 1980s: F-α and high-dose L-2 used for RCC treatment Pazopanib (US 2009, EU 2010) 3,4 Abeloff MD, et al. Clinical ncology 4th ed. Philadelphia, PA; 2. Coppin C, et al. Cochrane Database Syst Rev 2005;1:CD001425; 3. U.S. Food and Drug Administration ( 4. European Medicines Agency (
3 The PFS-plateau with VEGFR Multi-Kinaseinhibitors in 1st Line mrcc Motzer RJ, et al. Engl J Med 2007;356(2): Sternberg C, et al. J Clin ncol. 2010;28(6): Escudier B, et al. J Clin ncol 2010;28(13): Motzer RJ, et al. J Clin ncol 2013;31(30): Hutson TH, et al. J Clin ncol 31, 2013 (suppl 6; abstr LBA348) Eisen T, et al. J Clin ncol 31, 2013 (suppl; abstr 4506)
4 verall Survival in Sequential Randomized Trials TK-TK vs TK-mTR Historical F Suntinib Pivotal Trial RECRD-3 SU_EVE arm SWTCH SU-SR arm Motzer RJ, et al. Engl J Med 2007;356(2): Motzer RJ, et al. J Clin ncol 2014 Michel MS, ral Presentation at ASC GU 2014
5 What can we expect in a short term in the field of mrcc SURTME PRTECT CARMEA EVEREST SRCE S-TRAC ATLAS CheckMate 214 (ipi + nivo vs sun) ASSURE ADAPT ALLACE A (cabo vs sun) MPRT RAPD MPDL3280 +/- bevacizumab METER (cabo vs evero) CheckMate 25 (nivo vs evero) ephrectomy Y/ Adjuvancy Vaccines Targeted agents mmune Checkpoint
6 What can we expect in a short term in the field of mrcc SURTME PRTECT CARMEA EVEREST SRCE S-TRAC ATLAS CheckMate 214 (ipi + nivo vs sun) ASSURE ADAPT ALLACE A (cabo vs sun) MPRT RAPD MPDL3280 +/- bevacizumab METER (cabo vs evero) CheckMate 25 (nivo vs evero) ephrectomy Y/ Adjuvancy Vaccines Targeted agents mmune Checkpoint
7 The decision for ephrectomy is not difficult at the extremes in primary metastatic RCC C yes C no
8 CARMEA: Phase study of sunitinib versus nephrectomy + sunitinib Metastatic clear-cell RCC =576 R A D M Z A T ephrectomy Sunitinib 50 mg/day (Schedule 4/2) Sunitinib 50 mg/day (Schedule 4/2) Primary objective: s sunitinib alone non-inferior to nephrectomy plus sunitinib in terms of overall survival? P: Arnaud Mejean (CCAFU, HEGP, Paris, France) (CT )
9 SURTME: Phase study investigating immediate versus deferred nephrectomy Eligibility criteria Synchronous mrcc and primary tumour in situ =458 R A D M Z A T ephrectomy Sunitinib 50 mg/day (Schedule 4/2) Sunitinib 50 mg/day (Schedule 4/2) ephrectomy Primary endpoint: PFS Secondary endpoints: S, association with prognostic gene and protein expression profiles P: Axel Bex (C, Amsterdam, etherlands) (CT )
10 What can we expect in a short term in the field of mrcc SURTME PRTECT CARMEA EVEREST SRCE S-TRAC ATLAS CheckMate 214 (ipi + nivo vs sun) ASSURE ADAPT ALLACE A (cabo vs sun) MPRT RAPD MPDL3280 +/- bevacizumab METER (cabo vs evero) CheckMate 25 (nivo vs evero) ephrectomy Y/ Adjuvancy Vaccines Targeted agents mmune Checkpoint
11 ASSURE: Adjuvant sorafenib or sunitinib for unfavorable RCC (Phase ) Eligibility Patients with high- and intermediate-risk resected and non-metastatic RCC Clear-cell or non-clear cell RCC =1923 R A D M S A T Sunitinib once daily (4 weeks on/2 weeks off) for 1 year Sorafenib bid for 1 year Placebo for 1 years Primary endpoint: disease-free survival Secondary endpoints: S, decreases in left ventricular EF, frequency of clinically significant CHF (grade 3 or higher), QoL Haas et al. ASC GU 2015, abstract 403
12 ASSURE: Disease characteristics Sunitinib Sorafenib Placebo Total Histology Clear Cell 513 (79%) 519 (80%) 509 (79%) 1541 (79%) Papillary 39 (6%) 52 (8%) 59 (9%) 150 (8%) Chromophobe 40 (6%) 43 (7%) 28 (4%) 111 (6%) Mixed 31 (5%) 21 (3%) 31 (5%) 83 (4%) Unclassified 23 (4%) 14 (2%) 19 (3%) 56 (3%) Sarcomatoid Features 51 (8%) 58 (9%) 61 (10%) 170 (9%) Risk (as Stratified) ntermediate High 323 (50%) 324 (50%) 326 (50%) 973 (50%) Very High 324 (50%) 325 (50%) 321 (50%) 970 (50%) AJCC Stage 57 (9%) 61 (9%) 64 (10%) 182 (9%) 158 (25%) 167 (26%) 154 (24%) 479 (25%) 422 (65%) 409 (63%) 424 (66%) 1255 (65%) V 9 (1%) 12 (2%) 4 (1%) 25 (1%) Haas et al. ASC GU 2015, abstract 403
13 Proportion Alive and Disease-Free ASSURE: Disease-Free Survival Sunitinib Sorafenib Placebo Median 5.8 yrs Median 5.8 yrs Median 6.0 yrs Time (Months) Events Patients 5-yr DFS 97.5% C HR 97.5% C Sunitinib % % Sorafenib % % Placebo % % Haas et al. ASC GU 2015, abstract 403
14 Proportion Alive and Disease-Free ASSURE: DFS for Clear Cell Population Sunitinib Sorafenib Placebo Median 5.6 yrs Median 5.1 yrs Median 5.7 yrs Time (Months) Events Patients 5-yr DFS 97.5% C HR 97.5% C Sunitinib % % Sorafenib % % Placebo % % Haas et al. ASC GU 2015, abstract 403
15 ASSURE: Disease-Free Survival for Clear Cell Population During Treatment 84% vs 92% 50% improvement in DFS Haas et al. ASC GU 2015, abstract 403
16 Phase adjuvant studies in mrcc Study Arms Duration Primary endpoint ASSURE S-TRAC ATLAS SRCE PRTECT EVEREST Sunitinib Sorafenib Placebo Sunitinib Placebo Axitinib Placebo Sorafenib Sorafenib Placebo Pazopanib Placebo Everolimus Placebo 1 year 1923 Disease-free survival 1 year 720* Disease-free survival 3 years 690 Disease-free survival 3 years 1 year 3 years 1656 Disease-free survival 1 year 1500 Disease-free survival 54 weeks 1218 Recurrence-free survival
17 What can we expect in a short term in the field of mrcc SURTME PRTECT CARMEA EVEREST SRCE S-TRAC ATLAS CheckMate 214 (ipi + nivo vs sun) ASSURE ADAPT ALLACE A (cabo vs sun) MPRT RAPD MPDL3280 +/- bevacizumab METER (cabo vs evero) CheckMate 25 (nivo vs evero) ephrectomy Y/ Adjuvancy Vaccines Targeted agents mmune Checkpoint
18 Vaccines are in development in RCC Eligibility criteria: Metastatic and/or locally advanced ccrcc Favourable/intermediate risk HLA-A*02-positive o prior systemic therapy =330 R A D M S E D MA901 + GM-CSF + sunitinib Sunitinib MPRT randomised Phase trial Study completion: July 2015 Diagnosis of advanced kidney cancer Surgery Tumour sample taken =450 R A D M S E D Sunitinib + AGS-003 Sunitinib ADAPT randomised Phase trial Study completion: April 2016 AGS-003, autonomous dendritic cell product; ccrcc, clear cell renal cell carcinoma; GM-CSF, granulocyte macrophage colony-stimulating factor; MA901, consists of multiple tumour-associated peptides; SC, standard of care ADAPT study trial highlights. Available at: Accessed September 19, 2014; (CT ); (CT )
19 What can we expect in a short term in the field of mrcc SURTME PRTECT CARMEA EVEREST SRCE S-TRAC ATLAS CheckMate 214 (ipi + nivo vs sun) ASSURE ADAPT ALLACE A (cabo vs sun) MPRT RAPD MPDL3280 +/- bevacizumab METER (cabo vs evero) CheckMate 25 (nivo vs evero) ephrectomy Y/ Adjuvancy Vaccines Targeted agents mmune Checkpoint
20 PD-1 and PD-L1 antibodies in clinical development Target Agent Class PD-1 ivolumab (MDX1106, BMS ) Pembrolizumab (MK-3475) Pidilizumab (CT-011) gg4 fully human Ab gg4 engineered humanised Ab gg1 humanised Ab PD-L1 BMS (MDX-1105) MPDL3280A MED4736 Avelumab (MSB C) gg4 fully human Ab gg1 engineered fully human Ab gg1 engineered fully human Ab gg1 fully human Ab PD-1-positive T cells AMP-224 Fc of human gg-pd-l2 fusion
21 Monotherapy studies of checkpoint inhibitors in RCC: Summary of efficacy and safety Line Treatment PD-L1 Select. n RR (%) PFS (months) S (months) Adverse events (All grades) 1L+ ivolumab (0.3, 2, 10 mg/kg) 1 one A Fatigue (38 40%) ausea (8 18%) Pruritus (12 13%) Rash (4 12%) Diarrhoea (8 10%) 2L ivolumab (0.3, 2, 10 mg/kg) 2 one (5%) Fatigue (22 35%) Diarrhoea (3 15%) ausea (10 13%) Rash (7 13%) Pruritus (10 11%) 2L+ MPDL3280A 3 one A A Fatigue (22%) Decreased appetite (16%) Arthralgia (15%) Rash (15%) Diarrhoea (12%) Pruritis (12%) Pyrexia (12%) 1. Choueri et al ESM 2014; 2. Motzer et al J Clin ncol, Epub ahead of print (December 2014) 3. McDermott et al ESM 2014
22 CheckMate-025: Phase study of nivolumab vs everolimus in locally advanced/mrcc with prior anti-angiogenic therapy Eligibility: Advanced or mrcc with clear-cell component Received prior antiangiogenic therapy Progression on or after most recent therapy (within 6 months of study enrolment) Karnofsky PS 70 =822 RA D M SA T 1:1 ivolumab 3 mg/kg V every 2 weeks Everolimus 10 mg orally daily Treatment until disease progression or unacceptable toxicity Primary end point: S HR of 0.76 (32% increase in ms) required for positive study outcome Assumes a 4-month improvement in median S from 14 to 18 months Secondary end points: PFS, RR, DR, duration of S in PDL1-positive vs -negative subgroups, safety, disease-related symptom progression rate (CT )
23 Combination studies of checkpoint inhibitors in RCC: Summary of efficacy and safety Line Treatment PD-L1 Select. n RR (%) PFS (months) S (months) Adverse events (All grades) 1/2L ivolumab (2mg/kg or 5mg/kg Q3W) + sunitinib 1 one (1% & 5%) A Fatigue (82%) Diarrhoea (61%) Hypertension (49 %) ncreased ALT (39%) ncreased AST (36%) 2L+ ivolumab (2mg/kg Q3W) + Pazopanib 1 one (1% & 5%) A Fatigue (60%) Diarrhoea (60%) ncreased AST (30%) ncreased ALT (25%) Hypertension (25%) 1/2L ivolumab (3mg/kg) + pilimumab (1mg/kg Q3Wx4) 2 one A Fatigue (52%) Pruritus (38%) Rash (29%) Diarrhoea (29%) 1/2L ivolumab (1mg/kg) + pilimumab (3mg/kg Q3Wx4) 2 one A Fatigue (70%) ncreased ALT (39%) ncreased AST (39%) ausea (39%) Diarrhoea (35%) 1L MPDL3280A + bevacizumab (15mg/kg Q3W) 3,4 one (HC 1,2,3) A A Fatigue (46%) Pyrexia (37%) ausea (37%) Diarrhoea (31%) Decreased appetite (26%) Amin et al. ASC 2014; 2. Hammers et al. ASC 2014; 3. McDermott et al. ESM Lieu et al. ESM 2014
24 CheckMate 214: Phase study of nivolumab in combination with ipilimumab in first-line mrcc Eligibility: Patients with advanced RCC Treatment-naive =1070 RA D M Z A T ivolumab 3 mg/kg + ipilimumab 1 mg/kg q3wk* Sunitinib 50 mg (4 wk on/ 2 wk off) Primary end points: PFS, S Secondary end points: RR, adverse event rate *ivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks for 4 doses then nivolumab 3 mg/kg. (CT )
25 RAPD: Phase study of MPDL3280A as monotherapy or in combination with bevacizumab vs sunitinib in untreated advanced RCC Eligibility Locally advanced or mrcc with clear-cell and/or sarcomatoid component Previously untreated with any systemic therapy Karnofsky PS 70 = R A D M S A T MPDL3280A 1200 mg V q3w + bevacizumab 15 mg/kg V q3w MPDL3280A 1200 mg V q3w Sunitinib 50 mg/day 4/2 Primary endpoints: PFS per RECST v.1.1 via central CR assessment Secondary endpoints: PFS using investigator assessment per immune-related criteria, RR, duration of response, S, duration of response and PFS in patients progressing on sunitinib and MPDL alone arms who subsequently cross over to combination, safety, PK of MPDL3280A alone and in combination with bevacizumab (CT )
26 A phase, open-label, randomized study of MPDL3280A in combination with bevacizumab versus sunitinib in patients with untreated mrcc Eligibility: Unresectable advanced or metastatic RCC with clear-cell histology and/or sarcomatoid carcinoma Treatment-naïve All MSKCC risk scores are included =550 R A D M Z A T MPDL3280A 1200 mg V q3w + bevacizumab 15 mg/kg V q3w Sunitinib 50 mg (4 wk on/ 2 wk off) Stratification factors: Liver metastases (yes/no) MSKCC risk (0, 1-2, 3+) PD-L1 expression (C0, C1/2/3) Primary end point: PFS Secondary end points: RR, S, QL, toxicity profile
27 ivolumab (anti-pd-1) in combination with sunitinib/ pazopanib has shown encouraging anti-tumour activity Phase study of sunitinib/pazopanib + nivolumab in mrcc utcome Sunitinib + nivolumab (5 mg/kg) (n=33) Pazopanib + nivolumab (2 mg/kg) (n=20) RR, % Stable disease rate, % PFS rate at 24 weeks, % Grade 3 4 related AEs leading to discontinuation, % Four DLTs were observed in the pazopanib arm, leading to closure of this arm DLT, dose limiting toxicity; PD-1, programmed cell death 1 Amin et al. ASC 2014
28 Change in baseline target lesions (%) Maximum tumour burden reduction in baseline target lesions by nivolumab dose Treatment S + 2 (n=7) S + 5 (n=22) P + 2 (n=19) Patient Positive change in tumour burden indicates tumour growth; negative change indicates tumour change 2, nivolumab 2 mg/kg intravenous every 3 weeks; 5, nivolumab 5 mg/kg intravenous every 3 weeks; P, pazopanib; S, sunitinib Amin et al. ASC 2014
29 What can we expect in a short term in the field of mrcc SURTME PRTECT CARMEA EVEREST SRCE S-TRAC ATLAS CheckMate 214 (ipi + nivo vs sun) ASSURE ADAPT ALLACE A (cabo vs sun) MPRT RAPD MPDL3280 +/- bevacizumab METER (cabo vs evero) CheckMate 25 (nivo vs evero) ephrectomy Y/ Adjuvancy Vaccines Targeted agents mmune Checkpoint
30 METER: Phase study of second-line treatment with cabozantinib vs everolimus in mrcc Eligibility: mrcc with clear-cell component ne prior VEGF-targeted therapy =650 RA D M SA T Cabozantinib 60 mg orally daily Everolimus 10 mg orally daily Primary end point: PFS Study assumes mpfs of 5 months for everolimus and 7.5 months for cabozantinib. This provides for a HR of 0.67 and 90% power and requires 259 PFS events among the first 375 patients randomized Secondary end points: S, RR Assumes a median S of 15 months for everolimus and 20 months for cabozantinib. This provides for a HR of 0.75 and 80% power and requires 413 events Exploratory end points: patient-reported outcomes, biomarkers, safety, PK (CT )
31 ALLACE A031203: Randomized Phase Study Comparing Cabozantinib with Sunitinib in Patients with Previously Untreated Metastatic RCC Eligibility: patients with previously untreated clear cell mrcc with intermediate/poor risk =140 R A D M S A T Cabozantinib 60 mg orally daily Sunitinib 50 mg 4/2 schedule Primary end point: PFS Secondary end points: S, RR, Proportion of patients with unacceptable treatment related grade 3 or higher toxicity Exploratory end point: association between high MET expression and better PFS and S P: T. Choueri (CT )
32 The DART Study: Part 1 results of dalantercept plus axitinib dose escalation and expansion cohorts in advanced RCC Presented By Martin Voss at 2015 Genitourinary Cancers Symposium
33 Do not forget angiogenesis in mrcc: Axitinib + Dalantercept Presented By Martin Voss at 2015 Genitourinary Cancers Symposium
34 ESM 2014 RCC clinical guidelines Setting Risk group Standard ption First line Good/ntermediate risk Sunitinib [,A] Bevacizumab + F-α [,A] Pazopanib [,A] High-dose L2 [,C] Sorafenib [,B] Bevacizumab + low-dose F-α [,A] Poor risk Temsirolimus [,A] Sunitinib [,B] Sorafenib [,B] Second line Post cytokines Post VEGFR-TK Axitinib [,A] Sorafenib [,A] Pazopanib [,A] Axitinib [,B] Everolimus [,A] Sunitinib [,A] Sorafenib [,A] Third line Post two VEGFR-TKs Post VEGFR-TK and mtr inhibitor Everolimus [,A] Sorafenib [,B] ther VEGFR-TK [V,B] Rechallenge [V,B] Escudier B, et al. Ann ncol. 2014;25(Suppl. 3):iii49 iii56
35 Future ESM Guidelines?... Setting Tumour markers Treatment choice First-line therapy PD-L1 expression PD-L1/VHL null, BAP-1 WT PD-L1/VHL null, BAP-1 mutant mtr activation, high LDH ther mutation Anti-PD-1-based therapy Selective VEGF inhibitor VEGF inhibitor + agent X TR inhibitor Specific inhibitor Second-line therapy Same again? Presented by Atkins. KCS 2012
36 Muchas gracias
The Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationWill All Adjuvant Therapy Trials Be Negative in RCC?
Will All Adjuvant Therapy Trials Be Negative in RCC? Tim Eisen Eleventh European International Kidney Cancer Symposium 29-30 April 2016 Crowne Plaza Barcelona Fira Center, Barcelona, Spain Tim Eisen -
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationImmunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology
Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology 2013: Breakthrough of the Year December 20, 2013 Why immunotherapy? Immune
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationAtezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center
Atezolizumab Adjuvant Study: Medical Oncologist Perspective Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center Trial overview Key issues Outline Challenges with neoadjuvant therapy Placebo control
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationESMO Madrid, Spain Associate Professor Brian Costello Division of Medical Oncology, Genitourinary Tumour Group, Mayo Clinic, USA
ESMO 2017 - Madrid, Spain Associate Professor Brian Costello Division of Medical Oncology, Genitourinary Tumour Group, Mayo Clinic, USA HIGHLIGHTS ON RENAL CELL CARCINOMA CHECKMATE 214: EFFICACY AND SAFETY
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationAdvances in the Treatment of Renal Cell Carcinoma
Advances in the Treatment of Renal Cell Carcinoma Developed in collaboration Learning Objectives Upon completion, participants should be able to: Identify patients with metastatic renal cell carcinoma
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationWhat can we expect from running phase III trials: will all of them alter the current treatment algorithm?
What can we expect from running phase III trials: will all of them alter the current treatment algorithm? 8 th European International Kidney Cancer Symposium Budapest, May 2013 Martin Gore PhD FRCP Royal
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationCarcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia
Carcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia New target, new agent (James Brugarolas) Atezolizumab + Bevacizumab and PD-L1
More informationImmunotherapy for Genitourinary Cancers. Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI
Immunotherapy for Genitourinary Cancers Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI Disclosures Madison Vaccines Inc co-founder, IP, consultant
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
ipilimumab aligned with patient values. Although few patients had direct experience using this combination agent, patients indicated that side effects associated with nivolumab plus ipilimumab were few
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationUpdate on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
Xu and Wu Biomarker Research (2015) 3:5 DOI 10.1186/s40364-015-0030-7 REVIEW Open Access Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma Kevin Y Xu 1 and Shenhong
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationA Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of With or Without Bevacizumab vs in Untreated Metastatic Renal Cell Carcinoma Patients David McDermott, 1 Michael Atkins, 2 Robert Motzer, 3 Brian Rini, 4 Bernard Escudier, 5 Lawrence
More informationIs Immune Therapy the Holy Grail in Metastatic Kidney Cancer?
Is Immune Therapy the Holy Grail in Metastatic Kidney Cancer? New Frontiers in Urologic Oncology 8-2016 Mayer Fishman, MD PhD Member, Moffitt Cancer Center Department of Genitourinary Oncology Professor,
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationÍndice. Melanoma Cáncer de Pulmón Otros tumores
Índice Melanoma Cáncer de Pulmón Otros tumores Carcinoma de Vejiga Carcinoma de Células Renales Carcinoma de Cabeza y Cuello Carcinomas del tubo digestivo Cáncer de Mama MELANOMA CIRUGÍA CIRUGÍA + INFa
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More information